Gold prices hold losses as US-EU trade deal eases safe‑haven demand
NEW YORK -On Thursday, Baxter International Inc. (NYSE:BAX) the medical products company reported fourth-quarter earnings and revenue that beat analyst expectations and provided an upbeat outlook for 2025.
The positive quarterly results and outlook drove Baxter shares up 6.42% in pre-market trading following the earnings release.
The Deerfield, Illinois-based company posted adjusted earnings per share of $0.58 for the quarter, exceeding the consensus estimate of $0.52. Revenue came in at $2.75 billion, surpassing Wall Street’s forecast of $2.67 billion.
Baxter’s fourth-quarter sales from continuing operations increased 1% on a reported basis and 2% on a constant currency basis compared to the same period last year. The company’s Medical (TASE:BLWV) Products & Therapies segment saw flat sales growth, while Pharmaceuticals sales grew 8% at both reported and constant rates.
"Our 2024 performance and related strategic milestones reflect Baxter’s growing momentum in our pursuit of enhanced value for patients, healthcare providers, customers and shareholders," said Brent Shafer, chair and interim chief executive officer.
For the first quarter of 2025, Baxter expects adjusted earnings per share between $0.47 and $0.50. The company forecasts full-year 2025 adjusted EPS in the range of $2.45 to $2.55, above the average analyst estimate of $2.46.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.